A Study of XMT-2056 in advanced/recurrent solid tumors that express HER2.
5 Primary · 14 Secondary · Reporting Duration: 3 years
Experimental Treatment
171 Total Participants · 1 Treatment Group
Primary Treatment: XMT-2056 · No Placebo Group · Phase 1
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: